Results 41 to 50 of about 5,788 (178)

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients [PDF]

, 2017
International audienceBackground & aims - We report the first real-life results of the sofosbuvir+daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients.
Mathurin, Philippe, Fouchard-Hubert, Isabelle, V. de Ledinghen, Chazouillères, Olivier, J.P. Zarski, D’alteroche, Louis, S. Métivier, Geist, Claire, F. Zoulim, Diallo, Alpha, J.P. Bronowicki, A. Diallo, ANRS/AFEF HEPATHER study group, A. Tran, D. Thabut, D. Samuel, V. Petrov-Sanchez, I. Rosa, Fontaine, Hélène, Tran, Albert, Carrat, Fabrice, Guyader, Dominique, O. Chazouillères, Petrov-Sanchez, Ventzislava, Loustaud-Ratti, Véronique, Dorival, Céline, Riachi, Ghassan, C. Geist, L. Alric, Bourlière, Marc, P. Mathurin, F. Carrat, Ledinghen, Victor D. E., Samuel, Didier, C. Hezode, Habersetzer, François, Causse, Xavier, A. Minello, Hézode, Christophe, Bronowicki, Jean-Pierre, L. d\u27Altéroche, Gournay, Jérôme, D. Guyader, Alric, Laurent, Marcellin, Patrick, Rosa, Isabelle, D. Larrey, C. Dorival, I. Fouchard-Hubert, E. Saillard, Thabut, Dominique, X. Causse, Billaud, Eric, V. Loustaud-Ratti, Bourcier, Valérie, Zoulim, Fabien, G. Riachi, P. Marcellin, Saillard, Eric, Metivier, Sophie, Pol, Stanislas, S. Pol, Zarski, Jean-Pierre, J. Gournay, V. Bourcier, H. Fontaine, Larrey, Dominique, M. Bourlière, Minello, Anne, E. Billaud, Lucier, Sandy, S. Lucier, F. Habersetzer   +72 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF DACLATASVIR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY

, 2018
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of hepatitis-C drug - Daclatasvir in active pharmaceutical ingredient(API) form and in ...
CH. V. S Gautam*, N. Harika, V. Balaji, V. Srinivas Prasad
core   +1 more source

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients

Gut and Liver, 2018
Background/AimsAlthough daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed to evaluate the safety and efficacy of this
Shinya Taki, Hideyuki Tamai, Yoshiyuki Ida, Naoki Shingaki, Akira Kawashima, Ryo Shimizu, Kosaku Moribata, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture

Frontiers in Microbiology, 2022
We report a quantification of the decrease of effectiveness of antiviral agents directed to hepatitis C virus, when the agents are added during an ongoing infection in cell culture vs. when they are added at the beginning of the infection.
Carlos García-Crespo, Carlos García-Crespo, Lucía Vázquez-Sirvent, Lucía Vázquez-Sirvent, Pilar Somovilla, Pilar Somovilla, María Eugenia Soria, María Eugenia Soria, María Eugenia Soria, Isabel Gallego, Isabel Gallego, Ana Isabel de Ávila, Ana Isabel de Ávila, Brenda Martínez-González, Brenda Martínez-González, Antoni Durán-Pastor, Esteban Domingo, Esteban Domingo, Celia Perales, Celia Perales, Celia Perales, Celia Perales   +21 more
doaj   +1 more source

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy

Archives of Pharmaceutical Sciences Ain Shams University, 2021
Hepatitis C virus (HCV) was first identified in 1989. The situation in Egypt is really dire. The prevalence of HCV genotype 4 (GT-4) is 14.7%. About 10% of the middle-aged population (ages 15 to 59) is infected with HCV.
Heba Elbadawy, Sara Wahdan, Ebtehal El-Demerdash   +2 more
doaj   +1 more source

Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co‐infection among people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Among people with HIV with hepatitis C virus (HCV) co‐infection, we examined differences in haemoglobin A1c (HbA1c), total cholesterol (TC), low‐density lipoprotein (LDL), high‐density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score at 12‐months following direct acting antiviral (DAA) initiation ...
Raynell Lang, Elizabeth Humes, Asya Lyass, Leila H. Borowsky, Brenna Hogan, Arthur Y. Kim, Michael LaValley, Jennifer O. Lam, Ditipriya Bhar, Richard D. Moore, Frank Palella, Heidi Crane, Michael Horberg, Sonia Napravnik, Virginia A. Triant, Keri N. Althoff, on behalf of the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA)   +16 more
wiley   +1 more source

Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients [PDF]

, 2018
Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in ...
N. A. Mukhin, V. T. Ivashkin, D. T. Abdurakhmanov, Ye. . Sidorova, I. N. Tikhonov   +4 more
core   +1 more source

DEVELOPMENT AND VALIDATION OF A NEW RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION AND QUANTIFICATION OF SOFOSBUVIR AND DACLATASVIR

International Journal of Pharmacy & Integrated Health Sciences
Background: Sofosbuvir (SOF) and daclatasvir (DCV) are usually prescribed in combination for the treatment of hepatitis C worldwide. Objectives: In the present study a novel, simple, rapid, and cost-effective reversed-phase high performance liquid ...
Syed Hassan Murtaza, Ahmed Umer Sohaib Ahmed, Tassawer-e-Meran, Sonam Anees, Najam-ul-Hassan Khan, Kishwar Sultana   +5 more
doaj   +1 more source

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial

Journal of Viral Hepatitis, Volume 33, Issue 11, November 2026.
ABSTRACT The introduction of potent, well‐tolerated direct‐acting antivirals (DAAs) has transformed hepatitis C virus (HCV) therapy and spurred global elimination efforts. However, the extensive genetic diversity of HCV may affect antiviral efficacy, particularly in low and middle‐income regions where limited data currently exist.
Win Min Han, Sunil Solomon, Sandra Wagner‐Cardoso, Jiani Li, Aiyappa Parvangada, Mark Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evguenia Maiorova, David Wyles, the ACTG A5360 study team   +11 more
wiley   +1 more source